Lung Cancer
ETOP 14-18 CHESS
ETOP 14-18 CHESS
|
Title in German |
Eine Forschungsstudie, die die Wirksamkeit, Sicherheit und Verträglichkeit von Immuntherapie bei der gleichzeitigen Verabreichung mit Standard-Chemotherapie und Strahlentherapie bei Patienten mit nicht-kleinzelligem Lungenkrebs untersucht. |
|
Title in English |
A multicentre single arm phase II trial assessing the efficacy of immunotherapy, chemotherapy and stereotactic radiotherapy to metastases followed by definitive surgery or radiotherapy to the primary tumour, in patients with synchronous oligo-metastatic non-small cell lung cancer |
|
Description |
In the first part of the study, all patients receive standard chemotherapy (4-6 cycles) plus radiation therapy for their metastases. In addition, patients receive durvalumab (immunotherapy). An FDG/PET/CT scan will be performed three months after starting study treatment. All patients whose lung cancer has remained stable or reduced in size will receive either surgery or radiation therapy to treat their lung cancer. Treatment with durvalumab will be continued for a maximum of one year or until disease recurrence. Patients whose lung cancer disease has not remained stable or has expanded at the time of the FDG/PET/CT scan will stop all study treatment and move on to the follow-up phase of the study. After the end of the treatment period, all patients will be followed up for approximately 2.5 years, depending on when the patient entered the study. |
|
Phase/Biobank/ect. |
Phase 2 |
|
Head Clinical Trial |
Dr. med. Dr. sc. n. Ferdinando Cerciello |
|
Study-Nurse |
Fabiana Allenbach |
|
Back-up |
Nicole Corballis |
|
Status |
active in patient recruitment: 27.09.2023 |
|
BASEC Nummer |
2019-01234 |
|
KOFAM |
SNCTP000003439 |
|
WHO-Register-Nummer |
NCT03965468 |
Evaluation of Fluid Output Threshold for Safe Chest Tube Removal
|
Title in German |
Überprüfung der Flüssigkeitsmenge unter der die sichere Entfernung der Thoraxdrainage erfolgen kann – Eine Möglichkeit den Spitalaufenthalt zu verkürzen und die Schmerzen zu verbessern? Ein randomisierter kontrollierter Trial. |
|
Title in English |
Evaluation of Fluid Output Threshold for Safe Chest Tube Removal - A Potential Way to Decrease Length of Stay in Hospital and to Improve Postoperative Care After Lung Surgery? |
|
Description |
After partial lung removal, chest tubes (drainage tubes) are needed to help the lungs expand and prevent fluid from accumulating around the lungs. If there is no air supply, pay attention to the amount of fluid before removing the chest tube. Fluid is physiologically produced in the space between the lungs and the chest wall (pleural space) and swallowed again, so the question remains as to what amount of fluid can be removed from the tube without leaving too much fluid behind. Depending on the amount, remaining fluid can have an impact on the breathing situation. However, the inserted chest tube is also limiting. As long as the drainage is in place, the patient is tied to hospital care and requires additional pain therapy. Our goal is to be able to remove chest tubes as quickly as possible without taking unnecessary risks. |
|
Phase/Biobank/etc. |
|
|
Head Clinical Trial |
|
|
Study-Nurse |
|
|
Back-up |
|
|
Status |
open since 07/2019 |
|
BASEC-Nummer |
2017-00527 |
|
KOFAM |
|
|
WHO-Register-Nummer |
|
|
Insel-Nummer |
3728 |
LuCimiR
EORTC 1901 (PRIMALung study)
|
Title in German |
PRophylaktische Hirnbestrahlung oder aktive MAgnetresonanztomografische Überwachung von Patienten mit kleinzelligem Lungenkarzinom (PRIMALung-Studie) |
|
Title in English |
PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study) |
|
Description |
Patients with small cell lung cancer are usually treated with a combination of chemotherapy and radiation to the chest, and in some cases additional immunotherapy (drugs that stimulate the body's immune system). |
|
If the carcinoma spreads to the rest of the body (metastases), in many cases the brain is affected. Although brain irradiation is accepted as standard of care, current concerns about nervous system damage and the possibility of brain MRIs (magnetic resonance imaging) may make active monitoring a potentially better alternative to routine brain irradiation. In addition, there are open questions to be clarified about the role and timing of brain irradiation with increased use of immunotherapy. |
|
|
The aim of this study is to find out whether active surveillance via brain MRIs (magnetic resonance imaging) detects potential metastases in the brain earlier and leads to appropriate treatment without having a negative impact on survival compared to brain radiation when used in addition to brain metastases MRI monitoring is done. |
|
|
To find out whether the results of active monitoring via brain MRI are not caused purely by chance, we need to compare data from patients who were actively followed up via brain MRI with those from patients who received preventative brain irradiation. |
|
|
Therefore, the study participants are randomly assigned to one of two groups. One group receives daily preventive brain radiation for approximately 2 weeks and is then actively followed up via brain MRIs for up to 2 years. The other group will be actively followed up exclusively via brain MRIs for up to 2 years. |
|
|
Phase/Biobank/etc. |
|
|
Head Clinical Trial |
|
|
Study-Nurse |
|
|
Back-up |
|
|
Status |
aktive since 27.10.2022 |
|
BASEC-Nummer |
2022-00157 |
|
KOFAM |
SNCTP000004998 |
|
WHO-Register-Nummer |
NCT04790253 |
|
Insel-Nummer |
5206 |
SAKK 16/18
SAKK 16/18
|
Title in German |
SAKK 16/18: Strahlentherapie zur Verstärkung des Effekts einer prä-operativen (vor der Tumor-Operation) Immuntherapie bei Patienten mit lokal fortgeschrittenem nicht-kleinzelligem Bronchuskarzinom (NSCLC). Eine Phase-II-Studie, welche an mehreren Spitälern durchgeführt wird. |
|
Title in English |
Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III(N2) non-small cell lung cancer (NSCLC). A multicenter phase II trial. |
|
Description |
With this study we want to test a new treatment option for patients with locally advanced non-small cell lung cancer (NSCLC). The question is whether additional tumor radiation can improve the effect of immunotherapy before tumor surgery. The participants in this study receive the following therapies before tumor surgery: first chemotherapy, then immunotherapy with simultaneous radiation therapy. Radiation therapy is carried out according to one of three different protocols (= procedures) and the study also examines whether the 3 radiation protocols differ in their effect. |
|
Head Clinical Trial |
|
|
Study-Nurse |
|
|
Status |
active since 06.05.2020 |
|
BASEC Nummer |
2019-02378 |
|
KOFAM |
SNCTP000003022 |
|
WHO-Register-Nummer |
NCT03620669 |
|
Insel-Nummer |
4287 |
AMGEN 20210007
|
Title in German |
Erste Phase-1-Studie am Menschen zur Untersuchung der Sicherheit, Verträglichkeit und Pharmakokinetik von AMG 794 bei Patienten mit Claudin 6-positivem fortgeschrittenem/metastasiertem nicht-plattenepithelialem nicht-kleinzelligem Lungenkrebs oder epithelialem Eierstockkrebs |
|
Title in English |
Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 794 in Subjects With Claudin 6-positive Advanced/Metastatic Non-squamous Non-small Cell Lung Cancer or Epithelial Ovarian Cancer |
|
Phase/Biobank/ect. |
1 |
|
Head Clinical Trial |
|
|
Study-Nurse |
|
|
Back-up |
|
|
Back-up |
|
|
Status |
temporarily closed for patient recruitment: 04.05.2023 |
|
BASEC Nummer |
2022-01120 |
|
KOFAM |
|
|
EudraCT No. |
|
|
WHO-Register-Nummer |
|
|
Insel-Nummer |
5301 |
SAKK LuCa 2
|
Title in German |
Retrospektive und prospektive Registrierung von Patienten mit metastasiertem NSCLC, die typische und atypische EGFR-Mutationen aufweisen |
|
Title in English |
Retrospective and prospective registry of patients with metastatic NSCLC harboring typical and atypical EGFR mutations |
|
Description |
|
|
Phase |
Register |
|
Head Clinical Trial |
|
|
Study Coordinator |
|
|
Status |
active since 27.06.2023 |
|
BASEC-Nummer |
2023-00398 |
|
Insel-Nummer |
5487 |
Roche BO44426 Krascendo
|
Title in German |
Eine offene, multizentrische Phase-Ib/II-Studie zur Bewertung der Sicherheit, Wirksamkeit und Pharmakokinetik von GDC-6036 in Kombination mit anderen onkologischen Therapien bei Patienten mit zuvor nicht behandeltem fortgeschrittenem oder metastasiertem nicht-kleinzelligem Lungenkarzinom mit einer KRAS G12C- Mutation. |
|
Title in English |
A PHASE Ib/II, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, ACTIVITY, AND PHARMACOKINETICS OF GDC-6036 IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC NON−SMALL CELL LUNG CANCER WITH A KRAS G12C MUTATION |
|
Phase |
I |
|
Description |
This clinical trial will enroll patients with locally advanced or metastatic NSCLC that has not been previously treated. In addition, the NSCLC must be positive for PD-L1 protein and have the KRAS G12C mutation. The goal of this clinical trial is to test the safety and activity of GDC-6036 at various dosages in combination with pembrolizumab and to understand how the body processes these medications. Participants will receive the clinical trial treatment GDC-6036 in combination with pembrolizumab in 21-day treatment periods (called “treatment cycles”) until their investigator determines that they no longer benefit from the treatment. Participants will see the investigator every week for the first three treatment cycles, then every two weeks during cycles 4 and 5, and then every three weeks for the remaining treatment cycles. During these hospital visits, we will also check how the participant is responding to the treatment and whether they are experiencing any side effects. The total length of time participants take part in the clinical trial depends on how their NSCLC responds to treatment. It can last a day or more than 2 years. After administering the last dose of clinical study treatment, the investigator will examine participants every three months as long as they agree. Participants may discontinue study treatment and withdraw from the clinical trial at any time. |
|
Head Clinical Trial |
|
|
Study Nurse |
|
|
Study Nurse |
|
|
Status |
open for patient recruitment since Dec. 2023 (only arm: Divarasib 400mg + Pembrolizumab vs Divarasib 200mg + Pembrolizumab) |
|
BASEC-Nummer |
2023-01265 |
|
KOFAM |
SNCTP000005646 |
|
Insel-Nummer |
5524 |
Mesotheliom
eVOLVE-Meso
|
Title in German |
Eine Studie, um herauszufinden, ob Volrustomig in Kombination mit Chemotherapie bei Erwachsenen mit Pleuramesotheliom besser wirkt als Standardbehandlungen |
|
Title in English |
A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed Versus Platinum plus Pemetrexed or Nivolumab plus Ipilimumab in Participants with Unresectable Pleural Mesothelioma (eVOLVE-Meso) |
|
Descriptioin |
Researchers are looking for a better way to treat advanced pleural mesothelioma. Pleural mesothelioma is a type of cancer that affects the lining of the lungs. Advanced usually means that the cancer cannot be treated surgically. The most common cause of pleural mesothelioma is exposure to a toxic mineral called asbestos. There are two types of pleural mesotheliomas called epithelioid mesothelioma and non-epithelioid mesothelioma. The life expectancy of people with advanced pleural mesothelioma is low despite current standard treatments. Current standard treatments include nivolumab, ipilimumab or chemotherapy. This study will evaluate the investigational drug Volrustomig (MEDI5752) in combination with chemotherapy in advanced pleural mesothelioma. Volrustomig is intended to support the immune system in killing cancer cells. Researchers believe combining Volrustomig with chemotherapy could be more effective than standard treatments. |
|
Phase |
III |
|
Head Clinical Trial |
|
|
Study Nurse |
|
|
Back-up |
|
|
Status |
open for patient recruitment: 02.03.2024 |
|
BASEC-Nummer |
2023-01483 |
|
Nummer aus Studienregister (z.B. clinicaltrials.gov) |
SNCTP000005684 |
|
WHO-Register-Nummer |
NCT06097728 |
|
Insel-Nummer |
5641 |